EQT Life Sciences Exits Tubulis Stake in $5 Billion Sale to Gilead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GILD?
Source: PRnewswire
- Significant Transaction Value: EQT Life Sciences exits its minority stake in Tubulis through a sale to Gilead Sciences, valued at up to $5.0 billion, including $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments, reflecting strong market demand for innovative oncology platforms.
- Clinical Advancement: Tubulis' lead asset, TUB-040, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer, indicating its potential in the antibody-drug conjugate space and solidifying its position in the rapidly growing oncology market.
- Deepened Strategic Collaboration: Following the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, leveraging its Munich site to integrate discovery, manufacturing, and clinical capabilities to advance next-generation ADCs, enhancing Gilead's competitive edge in the global market.
- Remarkable Investment Returns: Since co-leading Tubulis' Series B2 financing in 2024, EQT Life Sciences has supported Tubulis' growth into a clinical-stage oncology player through active board involvement and strategic guidance, with this successful exit marking the effective implementation of its investment strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 140.130
Low
105.00
Averages
137.88
High
154.00
Current: 140.130
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Sciences Stock Falls 1.2% Following Announcement of Up to $5 Billion Acquisition of Germany's Tubulis
Stock Performance: Gilead Sciences shares have decreased by 1.2% following a significant acquisition.
Acquisition Details: The company has agreed to buy German biotech firm, which is valued at up to $5 billion.
See More
Gilead Acquires German Biotech Tubulis in Deal Worth Up to $5 Billion
- Acquisition Announcement: Gilead Sciences has announced its agreement to acquire German biotech company Tubulis GmbH.
- Financial Details: The cash deal is valued at up to $5 billion, aimed at enhancing Gilead's cancer drug pipeline.
See More
EQT Life Sciences Exits Tubulis Stake in $5 Billion Sale to Gilead
- Significant Transaction Value: EQT Life Sciences exits its minority stake in Tubulis through a sale to Gilead Sciences, valued at up to $5.0 billion, including $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments, reflecting strong market demand for innovative oncology platforms.
- Clinical Advancement: Tubulis' lead asset, TUB-040, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer, indicating its potential in the antibody-drug conjugate space and solidifying its position in the rapidly growing oncology market.
- Deepened Strategic Collaboration: Following the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, leveraging its Munich site to integrate discovery, manufacturing, and clinical capabilities to advance next-generation ADCs, enhancing Gilead's competitive edge in the global market.
- Remarkable Investment Returns: Since co-leading Tubulis' Series B2 financing in 2024, EQT Life Sciences has supported Tubulis' growth into a clinical-stage oncology player through active board involvement and strategic guidance, with this successful exit marking the effective implementation of its investment strategy.
See More
EQT Life Sciences Exits Tubulis Stake in $5 Billion Sale to Gilead
- Significant Transaction Value: EQT Life Sciences exits its minority stake in Germany-based Tubulis through a sale to Gilead Sciences for up to $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments, highlighting Tubulis' substantial potential in the antibody-drug conjugate space.
- Clinical Advancement: Tubulis' lead asset, TUB-040, is currently in Phase 1b/2 trials for platinum-resistant ovarian cancer and non-small cell lung cancer, and Gilead's acquisition is expected to accelerate its clinical development, further solidifying Tubulis' market position in oncology.
- Deepened Strategic Collaboration: The transaction will enable Tubulis to operate as a dedicated ADC research organization within Gilead, leveraging its Munich site for integrated discovery, manufacturing, and clinical capabilities to drive innovation in next-generation ADCs, enhancing competitiveness in the rapidly evolving oncology market.
- Investor Confidence Boosted: The successful exit by EQT Life Sciences reflects its commitment to early-stage scientific investments, aiding Tubulis in scaling through critical inflection points, and underscores the ongoing market demand for innovative oncology platforms, indicating strong future growth potential.
See More
Gilead Acquires German Biotech Company Tubulis for $3.15 Billion
- Acquisition Details: Gilead Sciences is acquiring Tubulis, a Germany-based clinical-stage biotech company, for $3.15 billion in cash, with the transaction expected to close in Q2 2026, significantly enhancing Gilead's competitive position in the antibody-drug conjugate (ADC) space.
- Core Assets of Tubulis: Tubulis' lead asset, TUB-040, is an ADC targeting platinum-resistant ovarian cancer and non-small cell lung cancer, currently in Phase 1b/2 development, and the acquisition will enable Gilead to accelerate its ADC pipeline development.
- EQT's Support Role: EQT Life Sciences played a crucial role in Tubulis' Series B2 financing in 2024, helping the company evolve into a leading global clinical-stage ADC player through board involvement and strategic guidance, demonstrating EQT's commitment to backing outstanding science early.
- Future Development Outlook: Post-acquisition, Tubulis will operate as a dedicated ADC research organization within Gilead, leveraging its Munich innovation hub to advance next-generation ADCs, further solidifying Gilead's position in the rapidly growing oncology market.
See More
Gilead Acquires Tubulis for $5B to Enhance Oncology Pipeline
- Acquisition Scale: Gilead announced its acquisition of Germany-based Tubulis GmbH for $5 billion, aiming to enhance its oncology pipeline, which will provide Gilead with key antibody-drug conjugate (ADC) therapies, particularly for ovarian cancer and other solid tumors.
- Cash Payment Structure: Under the transaction terms, Gilead will pay $3.15 billion in cash to acquire all outstanding equity of Tubulis, with up to $1.85 billion in contingent milestone payments, ensuring immediate value for Tubulis while incentivizing future R&D progress.
- Operational Integration Plan: Following the transaction's closure, Tubulis will operate as a dedicated ADC research organization within Gilead, with Munich serving as a hub for ADC innovation, manufacturing, and clinical capabilities, enhancing Gilead's R&D capacity and market competitiveness in oncology.
- Recent Acquisition Trend: This acquisition is part of Gilead's recent acquisition spree, following its $7.8 billion purchase of partner Arcellx in February and over $2.1 billion acquisition of US-based Ouro Medicines in March, demonstrating Gilead's proactive strategy to expand its product portfolio and market share.
See More
Gilead Sciences Stock Falls 1.2% Following Announcement of Up to $5 Billion Acquisition of Germany's Tubulis
Stock Performance: Gilead Sciences shares have decreased by 1.2% following a significant acquisition.
Acquisition Details: The company has agreed to buy German biotech firm, which is valued at up to $5 billion.
See More
Gilead Acquires German Biotech Tubulis in Deal Worth Up to $5 Billion
- Acquisition Announcement: Gilead Sciences has announced its agreement to acquire German biotech company Tubulis GmbH.
- Financial Details: The cash deal is valued at up to $5 billion, aimed at enhancing Gilead's cancer drug pipeline.
See More
EQT Life Sciences Exits Tubulis Stake in $5 Billion Sale to Gilead
- Significant Transaction Value: EQT Life Sciences exits its minority stake in Tubulis through a sale to Gilead Sciences, valued at up to $5.0 billion, including $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments, reflecting strong market demand for innovative oncology platforms.
- Clinical Advancement: Tubulis' lead asset, TUB-040, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer, indicating its potential in the antibody-drug conjugate space and solidifying its position in the rapidly growing oncology market.
- Deepened Strategic Collaboration: Following the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, leveraging its Munich site to integrate discovery, manufacturing, and clinical capabilities to advance next-generation ADCs, enhancing Gilead's competitive edge in the global market.
- Remarkable Investment Returns: Since co-leading Tubulis' Series B2 financing in 2024, EQT Life Sciences has supported Tubulis' growth into a clinical-stage oncology player through active board involvement and strategic guidance, with this successful exit marking the effective implementation of its investment strategy.
See More
EQT Life Sciences Exits Tubulis Stake in $5 Billion Sale to Gilead
- Significant Transaction Value: EQT Life Sciences exits its minority stake in Germany-based Tubulis through a sale to Gilead Sciences for up to $3.15 billion in upfront cash and up to $1.85 billion in contingent milestone payments, highlighting Tubulis' substantial potential in the antibody-drug conjugate space.
- Clinical Advancement: Tubulis' lead asset, TUB-040, is currently in Phase 1b/2 trials for platinum-resistant ovarian cancer and non-small cell lung cancer, and Gilead's acquisition is expected to accelerate its clinical development, further solidifying Tubulis' market position in oncology.
- Deepened Strategic Collaboration: The transaction will enable Tubulis to operate as a dedicated ADC research organization within Gilead, leveraging its Munich site for integrated discovery, manufacturing, and clinical capabilities to drive innovation in next-generation ADCs, enhancing competitiveness in the rapidly evolving oncology market.
- Investor Confidence Boosted: The successful exit by EQT Life Sciences reflects its commitment to early-stage scientific investments, aiding Tubulis in scaling through critical inflection points, and underscores the ongoing market demand for innovative oncology platforms, indicating strong future growth potential.
See More
Gilead Acquires German Biotech Company Tubulis for $3.15 Billion
- Acquisition Details: Gilead Sciences is acquiring Tubulis, a Germany-based clinical-stage biotech company, for $3.15 billion in cash, with the transaction expected to close in Q2 2026, significantly enhancing Gilead's competitive position in the antibody-drug conjugate (ADC) space.
- Core Assets of Tubulis: Tubulis' lead asset, TUB-040, is an ADC targeting platinum-resistant ovarian cancer and non-small cell lung cancer, currently in Phase 1b/2 development, and the acquisition will enable Gilead to accelerate its ADC pipeline development.
- EQT's Support Role: EQT Life Sciences played a crucial role in Tubulis' Series B2 financing in 2024, helping the company evolve into a leading global clinical-stage ADC player through board involvement and strategic guidance, demonstrating EQT's commitment to backing outstanding science early.
- Future Development Outlook: Post-acquisition, Tubulis will operate as a dedicated ADC research organization within Gilead, leveraging its Munich innovation hub to advance next-generation ADCs, further solidifying Gilead's position in the rapidly growing oncology market.
See More
Gilead Acquires Tubulis for $5B to Enhance Oncology Pipeline
- Acquisition Scale: Gilead announced its acquisition of Germany-based Tubulis GmbH for $5 billion, aiming to enhance its oncology pipeline, which will provide Gilead with key antibody-drug conjugate (ADC) therapies, particularly for ovarian cancer and other solid tumors.
- Cash Payment Structure: Under the transaction terms, Gilead will pay $3.15 billion in cash to acquire all outstanding equity of Tubulis, with up to $1.85 billion in contingent milestone payments, ensuring immediate value for Tubulis while incentivizing future R&D progress.
- Operational Integration Plan: Following the transaction's closure, Tubulis will operate as a dedicated ADC research organization within Gilead, with Munich serving as a hub for ADC innovation, manufacturing, and clinical capabilities, enhancing Gilead's R&D capacity and market competitiveness in oncology.
- Recent Acquisition Trend: This acquisition is part of Gilead's recent acquisition spree, following its $7.8 billion purchase of partner Arcellx in February and over $2.1 billion acquisition of US-based Ouro Medicines in March, demonstrating Gilead's proactive strategy to expand its product portfolio and market share.
See More
